Hepatitis C in the Direct-Acting Antiviral Era: Immunopathogenesis, Dendritic Cells and Modern Clinical Management

Area of Science:

• Immunology
• Hepatology
• Virology

Background:

• Hepatitis C virus (HCV) causes chronic liver disease, cirrhosis, and cancer, affecting millions globally.
• Effective viral clearance relies on robust innate and adaptive immune responses, including T-cell activation and memory.
• Dendritic cells (DCs) are key in bridging innate and adaptive immunity during viral infections.

Purpose of the Study:

• To review the critical role of dendritic cells (DCs) in Hepatitis C virus (HCV) infection.
• To analyze DC phenotype and function in both acute and chronic HCV disease.
• To summarize immune system changes following direct-acting antiviral (DAA)-induced sustained virologic response (SVR).

Main Methods:

• Literature review focusing on dendritic cell function in HCV infection.
• Analysis of DC phenotype and cytokine production (IL-12, IL-10) in acute vs. chronic HCV.
• Examination of immune responses post-direct-acting antiviral (DAA) therapy and sustained virologic response (SVR).

Main Results:

• Chronic HCV infection is associated with reduced numbers of dendritic cells (DCs) and impaired maturation.
• DCs in chronic HCV exhibit altered function, including lower IL-12 and higher IL-10 production, weakening T-cell responses.
• Direct-acting antiviral (DAA) therapy leads to sustained virologic response (SVR) and partial immune recovery, but some immune dysregulation may persist.

Conclusions:

• Dendritic cells (DCs) play a vital role in controlling Hepatitis C virus (HCV) infection, with impaired function in chronic disease.
• Direct-acting antiviral (DAA) therapy is highly effective for HCV, improving patient outcomes.
• Despite treatment success, residual immune dysregulation warrants further investigation for complete viral clearance and long-term health.